Business
ZYUS Life Sciences Expands U.S. Patent Portfolio with Second Pain Management Patent
ZYUS Life Sciences Expands U.S. Patent Portfolio with Second Pain Management Patent Canad...
About this update from Zyus Life Sciences Corporation
[{"type":"text","content":"\n\n\nZYUS Life Sciences Expands U.S. Patent Portfolio with Second Pain Management Patent\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nCanada NewsWire\n\n\nIssuance of U.S. patent supports ongoing clinical research in chronic and neuropathic pain SASKATOON, SK, May 5, 2026 /CNW/ - ZYUS Life Sciences Corporation (the \"Company\") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, announced today that the United States Patent and Trademark Office (\"USPTO\") has issued U.S. Patent No. 12,616,704, entitled CANNABICHROMENE FORMULATION FOR PAIN MANAGEMENT on today's date.  The patent, held by ZYUS' wholly owned subsidiary, ZYUS Life Sciences Inc., is based on International Patent Application No. PCT/CA2021/050430 and covers a novel, non-intoxicating approach to pain management.\n\n\n\n\n\n\n\nThis represents the Company's second U.S. patent in pain management, further strengthening its intellectual property portfolio. The Company's first U.S. patent supports ZYUS' lead drug candidate, Trichomylin® softgel capsules, a proprietary fixed-dose combination for pain management by delivering a balanced ratio of cannabinoids, which includes cannabichromene (\"CBC\").The newly issued patent relates to the Company's second drug candidate, further expanding its pipeline of novel, proprietary, non-opioid therapies and supports ongoing clinical research targeting neuropathic pain, including peripheral neuropathy, such as diabetic and cancer-related neuropathies. These indications are consistent with those covered under the Company's first patent, reinforcing ZYUS' focused approach to pain management.The issuance of the U.S. patent further strengthens the continued development of the Company's second drug candidate, for which Investigational New Drug (IND)-enabling studies have been completed to support the potential initiation of clinical trials in the United States. The patent provides additional intellectual property protection al...